1. A clinician prescribing terbinafine for onychomycosis asks a pharmacist to clarify terbinafine's antifungal activity profile. Which statement most accurately describes terbinafine's fungicidal versus fungistatic activity across clinically relevant fungal pathogens?
A) Terbinafine is fungicidal against both dermatophytes and Candida species, making spectrum determination by culture unnecessary before treatment
B) Terbinafine is fungistatic against dermatophytes at standard oral doses; fungicidal activity requires concentrations achievable only with topical formulations applied directly to the nail bed
C) Terbinafine is fungicidal against dermatophytes due to toxic squalene accumulation, but has poor activity against Candida species because the squalene epoxidase pathway in Candida does not lead to equivalent toxic squalene buildup
D) Terbinafine is fungicidal against all molds including Aspergillus fumigatus, making it an appropriate empirical agent for invasive fungal infections in immunocompromised patients
E) Terbinafine is uniformly fungistatic regardless of organism; its clinical superiority over griseofulvin derives from pharmacokinetic advantages in nail penetration rather than from any mechanism-based activity difference
ANSWER: C
Rationale:
Terbinafine is fungicidal against dermatophytes because inhibition of squalene epoxidase in these organisms leads to intracellular accumulation of squalene to toxic concentrations, directly destabilizing the cell membrane. This toxic squalene accumulation is the primary basis for fungicidal activity. However, against Candida species, the same enzyme inhibition does not produce equivalent lethal squalene accumulation; the organism tolerates the pathway disruption differently, and terbinafine has poor antifungal efficacy against Candida at clinically achievable concentrations. This spectrum limitation is clinically important because onychomycosis can be caused by dermatophytes, non-dermatophyte molds, or Candida, and terbinafine's activity does not cover the latter — confirming dermatophyte etiology by culture before prescribing is therefore standard practice.
Option A: Option A is incorrect because terbinafine is not reliably active against Candida species; it is fungicidal against dermatophytes but has poor Candida coverage, which is precisely why pre-treatment culture confirmation matters.
Option B: Option B is incorrect because terbinafine's fungicidal activity against dermatophytes occurs with systemic oral dosing as well as topically; it is not limited to topical formulations — the drug achieves fungicidal concentrations in nail and skin after oral administration.
Option D: Option D is incorrect because terbinafine does not have established fungicidal activity against Aspergillus fumigatus and is not used for invasive mold infections; its clinical spectrum is primarily dermatophytes, and empirical use in invasive fungal disease is not supported.
Option E: Option E is incorrect because the distinction between fungicidal and fungistatic activity for terbinafine is mechanism-based: squalene accumulation in dermatophytes is directly toxic, producing genuine fungicidal activity, which is a meaningful pharmacodynamic difference rather than a purely pharmacokinetic advantage.
2. An infectious disease fellow is reviewing the pharmacokinetics of flucytosine before initiating treatment for cryptococcal meningitis in a patient who has functioning gastrointestinal absorption. The fellow asks whether intravenous administration offers any pharmacokinetic advantage over oral dosing. Which statement is correct?
A) Flucytosine has oral bioavailability exceeding 90%, making the oral and intravenous routes pharmacokinetically interchangeable; no meaningful difference in systemic drug exposure exists between routes in patients with intact gastrointestinal absorption
B) Flucytosine oral bioavailability is approximately 40 to 50% because of significant first-pass hepatic metabolism; intravenous administration is preferred whenever systemic drug exposure is critical
C) Flucytosine oral bioavailability is highly variable (10 to 80%) depending on gastric pH; co-administration with a proton pump inhibitor is required to ensure reliable absorption
D) Flucytosine is poorly absorbed orally because it is a charged molecule at physiological pH; bioavailability improves to approximately 60% when taken with a high-fat meal that neutralizes gastric acid
E) Flucytosine oral bioavailability is approximately 70%, which is adequate for mild infections but intravenous dosing is required for central nervous system infections because the oral route does not achieve sufficient cerebrospinal fluid concentrations
ANSWER: A
Rationale:
Flucytosine has oral bioavailability exceeding 90%, which is exceptionally high for an antifungal agent. This near-complete oral absorption means that the oral and intravenous routes produce essentially equivalent systemic drug concentrations, and the routes are pharmacokinetically interchangeable in patients with intact gastrointestinal function. This property is clinically important because it allows seamless transition between intravenous and oral administration during prolonged treatment without requiring dose adjustment, and it means that oral flucytosine achieves the same high cerebrospinal fluid (CSF) concentrations — 70 to 85% of plasma — as intravenous dosing. The high bioavailability reflects flucytosine's hydrophilic, low-molecular-weight structure and the absence of significant first-pass hepatic metabolism; more than 90% of absorbed drug reaches the systemic circulation unchanged.
Option B: Option B is incorrect because significant first-pass hepatic metabolism is not a feature of flucytosine pharmacokinetics; the drug is not substantially metabolized in the liver and is excreted predominantly as unchanged drug in urine, so oral bioavailability is not reduced by hepatic extraction.
Option C: Option C is incorrect because flucytosine absorption is not gastric-pH-dependent; it does not require proton pump inhibitor co-administration, and its absorption is not limited by pH variability in the gastrointestinal tract.
Option D: Option D is incorrect because flucytosine is hydrophilic rather than charged in a way that impairs absorption, and its absorption is not fat-dependent — unlike griseofulvin, which requires fat co-administration for adequate microsize absorption.
Option E: Option E is incorrect because oral flucytosine achieves the same CSF concentrations as intravenous flucytosine at equivalent systemic doses; the route of administration does not limit CNS penetration, which is determined by the drug's intrinsic pharmacokinetic properties.
3. A 44-year-old woman with a mechanical heart valve on stable warfarin anticoagulation (INR (international normalized ratio) 2.6, therapeutic range 2.5–3.5) is prescribed a 10-week course of griseofulvin for tinea capitis. Two weeks later her INR is 1.7. Which statement correctly identifies the mechanism and clinical implication of this interaction?
A) Griseofulvin inhibits CYP2C9 (cytochrome P450 2C9), the primary enzyme responsible for warfarin S-enantiomer metabolism, reducing warfarin clearance and producing supratherapeutic INR elevation
B) Griseofulvin displaces warfarin from plasma albumin binding sites, transiently reducing total warfarin concentration while increasing the free fraction; the net effect is a transient INR reduction that self-corrects without dose adjustment
C) Griseofulvin chelates vitamin K in the gastrointestinal tract, reducing its absorption and paradoxically enhancing warfarin's anticoagulant effect, which explains the supratherapeutic INR seen in this patient
D) Griseofulvin induces CYP3A4 (cytochrome P450 3A4) and CYP1A2 (cytochrome P450 1A2), increasing hepatic warfarin metabolism and reducing plasma warfarin concentrations, which lowers anticoagulant effect and decreases the INR
E) Griseofulvin competes with warfarin for renal tubular secretion, reducing warfarin excretion and increasing its plasma half-life, which would be expected to elevate rather than reduce the INR
ANSWER: D
Rationale:
Griseofulvin is an inducer of CYP3A4 and CYP1A2. Warfarin undergoes hepatic metabolism by multiple CYP isoforms, and induction of these enzymes by griseofulvin increases the rate of warfarin clearance, reducing plasma warfarin concentrations and thereby lowering anticoagulant effect — manifesting as a reduced INR. In this patient, the INR falling from 2.6 to 1.7 after two weeks of griseofulvin represents a clinically significant reduction in anticoagulation below the therapeutic target of 2.5 to 3.5, placing her at increased thromboembolic risk with a mechanical valve. Management requires more frequent INR monitoring and a warfarin dose increase during the griseofulvin course, with subsequent dose reduction when griseofulvin is discontinued as induced enzyme activity returns to baseline.
Option A: Option A is incorrect because griseofulvin is a CYP inducer, not a CYP2C9 inhibitor; CYP2C9 inhibition (as seen with fluconazole, for example) would increase warfarin concentrations and elevate the INR, which is the opposite of the clinical finding here.
Option B: Option B is incorrect because protein binding displacement is not the operative mechanism for this interaction, and a self-correcting transient effect does not explain the persistent INR reduction seen after two weeks; the dominant mechanism is enzyme induction reducing warfarin clearance.
Option C: Option C is incorrect because griseofulvin does not chelate vitamin K and does not enhance warfarin anticoagulant effect; the interaction produces reduced rather than enhanced anticoagulation, as demonstrated by the falling INR.
Option E: Option E is incorrect because warfarin is not significantly eliminated by renal tubular secretion; it is hepatically metabolized, and competition at renal transporters is not the mechanism of this interaction.
4. A patient completes a 12-week course of terbinafine for onychomycosis. Three weeks after the final dose, she begins a new prescription for metoprolol (a beta-blocker metabolized primarily by CYP2D6) for newly diagnosed hypertension. Her physician asks whether the prior terbinafine course could still influence metoprolol pharmacokinetics. Which statement correctly characterizes the relevant property of terbinafine's CYP2D6 inhibition?
A) Terbinafine produces reversible competitive inhibition of CYP2D6; enzyme activity fully recovers within 24 to 48 hours of the last dose, so no clinically relevant interaction with metoprolol is expected three weeks after stopping terbinafine
B) Terbinafine produces mechanism-based irreversible inhibition of CYP2D6 by covalently inactivating the enzyme; inhibitory effects persist for weeks after discontinuation as newly synthesized CYP2D6 enzyme gradually replaces the inactivated pool, so residual interaction with metoprolol remains possible at three weeks
C) Terbinafine inhibits CYP2D6 indirectly by depleting NADPH (nicotinamide adenine dinucleotide phosphate) cofactors required for CYP enzyme function; recovery depends on NADPH regeneration, which takes approximately five days
D) Terbinafine downregulates CYP2D6 gene transcription through nuclear receptor activation; enzyme recovery requires new protein synthesis driven by de-repression of the gene, which takes approximately four to seven days after the drug is stopped
E) Terbinafine inhibits CYP2D6 only in the gastrointestinal wall during drug absorption; systemic CYP2D6 activity in the liver is unaffected, so hepatically metabolized drugs like metoprolol are not subject to clinically meaningful interaction
ANSWER: B
Rationale:
Terbinafine produces mechanism-based (also called mechanism-dependent or suicide) inhibition of CYP2D6. In mechanism-based inhibition, the drug is converted by the enzyme into a reactive intermediate that covalently and irreversibly inactivates the enzyme active site. Because the inactivation is irreversible, recovery of CYP2D6 activity depends entirely on de novo synthesis of new enzyme protein — a process that takes weeks, not hours or days. The half-life of CYP2D6 enzyme turnover is approximately one to two weeks in healthy adults, meaning that at three weeks post-terbinafine, residual CYP2D6 inhibition may still be present, and metoprolol — a CYP2D6 substrate with a relatively narrow therapeutic window — may accumulate to higher-than-expected concentrations. Clinicians should be aware of this persisting interaction when initiating CYP2D6-metabolized drugs weeks after terbinafine discontinuation.
Option A: Option A is incorrect because terbinafine's inhibition of CYP2D6 is mechanism-based and irreversible, not competitive and reversible; the distinction is critical because recovery from reversible competitive inhibition mirrors drug elimination (hours to days), whereas recovery from mechanism-based inhibition requires new enzyme synthesis (weeks).
Option C: Option C is incorrect because terbinafine does not inhibit CYP2D6 through NADPH depletion; mechanism-based inhibition involves covalent modification of the enzyme active site by a reactive metabolite formed during catalysis, not cofactor depletion.
Option D: Option D is incorrect because terbinafine does not downregulate CYP2D6 gene transcription through nuclear receptor activation; that mechanism describes enzyme induction in reverse (downregulation) and is not the established mechanism for terbinafine's CYP2D6 interaction.
Option E: Option E is incorrect because terbinafine's CYP2D6 inhibition is hepatic as well as intestinal; metoprolol undergoes extensive first-pass and systemic hepatic CYP2D6 metabolism, and the interaction occurs at the hepatic level.
5. A clinical microbiologist reviews a case where flucytosine susceptibility testing on a Candida isolate shows high-level resistance. The attending physician asks which molecular mechanisms account for primary resistance to flucytosine in Candida species. Which answer most accurately describes the established resistance pathways?
A) Resistance arises primarily through upregulation of efflux pumps (CDR1 and MDR1) that actively expel flucytosine from the fungal cell before intracellular conversion to active metabolites can occur
B) Resistance is mediated by mutation of the flucytosine binding site on thymidylate synthase, which prevents FdUMP (fluorodeoxyuridine monophosphate) from inhibiting DNA synthesis while leaving RNA synthesis disruption intact
C) Resistance develops through increased expression of ergosterol biosynthesis enzymes that compensate for membrane disruption caused by flucytosine's active metabolites, restoring membrane integrity
D) Resistance occurs when Candida species acquire horizontal gene transfer of a cytosine deaminase variant from co-infecting bacterial flora that converts flucytosine to an inactive rather than active metabolite
E) Resistance arises through loss-of-function mutations at three points in the flucytosine activation pathway: cytosine permease (preventing cellular uptake), cytosine deaminase (preventing conversion to 5-fluorouracil (5-FU)), or URA3/URA5 enzymes (preventing conversion of 5-FU to active nucleotides that inhibit DNA and RNA synthesis)
ANSWER: E
Rationale:
Flucytosine resistance in Candida species arises through loss-of-function mutations at three sequential steps in the drug's intracellular activation pathway. First, mutations in the genes encoding cytosine permease (FCY2 and UPT1) prevent active transport of flucytosine into the fungal cell. Second, mutations in cytosine deaminase (FCY1) prevent conversion of intracellular flucytosine to 5-fluorouracil (5-FU), the key toxic intermediate. Third, mutations in URA3 (orotidine-5-phosphate decarboxylase) or URA5 (orotate phosphoribosyltransferase) prevent the downstream phosphorylation of 5-FU to fluorodeoxyuridine monophosphate (FdUMP) and fluorouridine triphosphate (FUTP), the active metabolites that inhibit thymidylate synthase and disrupt RNA synthesis respectively. Any single mutation at any of these three nodes can confer resistance, which explains why resistance emerges rapidly during monotherapy — selection of pre-existing mutants at any node is sufficient. Intrinsic resistance in C. krusei (Pichia kudriavzevii) reflects constitutive absence or dysfunction of these pathway components.
Option A: Option A is incorrect because the primary flucytosine resistance mechanism in Candida is not efflux pump overexpression (CDR1/MDR1 efflux is the dominant resistance mechanism for azoles, not for flucytosine); resistance to flucytosine is mediated through loss of the activation enzymes rather than through increased drug efflux.
Option B: Option B is incorrect because flucytosine resistance does not occur through mutation of the thymidylate synthase binding site for FdUMP; the resistance mutations are in the upstream activation enzymes that produce FdUMP in the first place, not in the downstream target.
Option C: Option C is incorrect because upregulation of ergosterol biosynthesis enzymes is not an established flucytosine resistance mechanism; ergosterol pathway compensation is relevant to polyene resistance, not to antimetabolite resistance.
Option D: Option D is incorrect because horizontal transfer of a variant cytosine deaminase from bacterial flora is not a recognized clinical resistance mechanism; resistance arises through endogenous fungal gene mutations, not through acquisition of bacterial enzyme variants.
6. A pharmacist is counseling a patient newly prescribed ultramicrosize griseofulvin (Gris-PEG) after previously taking microsize griseofulvin (Griseofulvin V) at 500 mg once daily. The patient asks why the new prescription is written for a lower dose. Which statement correctly explains the pharmacokinetic basis for the dose difference between formulations?
A) Ultramicrosize griseofulvin has a longer plasma half-life than microsize because it undergoes less CYP3A4 metabolism; the lower dose reflects reduced hepatic extraction rather than improved absorption
B) Ultramicrosize griseofulvin is more potent at the tubulin binding site than microsize griseofulvin due to differences in stereochemical presentation; a lower dose achieves the same receptor occupancy
C) Ultramicrosize griseofulvin achieves more consistent and complete oral absorption (approximately 70% bioavailability) due to smaller particle size enhancing intestinal solubilization, allowing a lower absolute dose to achieve equivalent plasma concentrations compared to microsize formulation
D) Ultramicrosize griseofulvin bypasses gastrointestinal absorption entirely through lymphatic uptake, producing 100% bioavailability independent of food intake; the lower dose reflects this complete systemic delivery
E) Ultramicrosize griseofulvin has superior nail and skin penetration compared to microsize because smaller particles pass through the dermal capillary wall more readily; the dose difference reflects pharmacodynamic rather than pharmacokinetic differences
ANSWER: C
Rationale:
Griseofulvin is available in two oral formulations that differ in particle size, which directly affects intestinal dissolution and absorption. Microsize griseofulvin has highly variable oral bioavailability of approximately 25 to 70% depending on fat co-administration, reflecting the relatively poor aqueous solubility of larger particles. Ultramicrosize griseofulvin (Gris-PEG) uses a polyethylene glycol dispersion to produce much smaller particles with a greater surface area, which enhances intestinal lipid solubilization and produces more consistent and complete absorption — approximately 70% bioavailability with lower inter-patient variability. Because the ultramicrosize formulation delivers more drug to the systemic circulation per milligram administered, a lower absolute dose achieves equivalent plasma concentrations. Typical adult dosing for tinea capitis is approximately 500 mg once daily (microsize) versus 375 mg once daily (ultramicrosize). Both formulations still benefit from fat co-administration for optimal absorption, though the ultramicrosize formulation is less critically dependent on it.
Option A: Option A is incorrect because the dose difference between formulations is attributable to improved absorption (bioavailability), not to a difference in plasma half-life or hepatic CYP3A4 extraction; both formulations are metabolized by CYP3A4 at equivalent rates once absorbed.
Option B: Option B is incorrect because ultramicrosize and microsize griseofulvin are the same chemical entity with the same binding affinity for tubulin; the pharmacodynamic interaction with the target is identical between formulations, and the dose difference is entirely pharmacokinetic.
Option D: Option D is incorrect because griseofulvin does not achieve 100% bioavailability through lymphatic uptake; it is absorbed through the gastrointestinal mucosa by a lipid-dependent pathway, and bioavailability remains approximately 70% for the ultramicrosize formulation, not 100%.
Option E: Option E is incorrect because the dose difference between formulations reflects pharmacokinetic differences in systemic absorption, not differences in tissue penetration at the site of action; once absorbed, both formulations distribute to skin, hair, and nails by the same mechanism.
7. A clinical pharmacologist is explaining why flucytosine achieves excellent penetration into the cerebrospinal fluid (CSF) and why its distribution characteristics differ from those of amphotericin B. Which pharmacokinetic property of flucytosine best accounts for both its high CSF penetration and its volume of distribution of approximately 0.6 L/kg?
A) Flucytosine is hydrophilic with a volume of distribution approximating total body water (approximately 0.6 L/kg) and minimal plasma protein binding (approximately 4%), properties that allow uniform distribution into aqueous body compartments including the CSF without the deep tissue sequestration seen with lipophilic drugs
B) Flucytosine has a volume of distribution of approximately 0.6 L/kg because it is highly protein-bound (approximately 85%), which restricts it to the vascular compartment and reduces apparent distribution into peripheral tissue; CSF penetration occurs via active transport at the choroid plexus
C) Flucytosine has a large volume of distribution (approximately 0.6 L/kg reflects extensive intracellular sequestration) comparable to that of amphotericin B lipid complex; the high CSF concentrations reflect intrathecal drug release from tissue depots
D) Flucytosine achieves its volume of distribution of approximately 0.6 L/kg through selective concentration in adipose tissue, which acts as a depot for slow drug release; high CSF penetration results from this prolonged systemic drug exposure rather than from direct passive diffusion
E) Flucytosine has a volume of distribution of approximately 0.6 L/kg because it undergoes extensive biliary excretion with enterohepatic recycling; the resulting prolonged systemic half-life allows CSF equilibration over multiple dosing cycles
ANSWER: A
Rationale:
Flucytosine is a hydrophilic (water-soluble) small molecule with minimal plasma protein binding of approximately 4%. Its volume of distribution of approximately 0.6 L/kg corresponds closely to total body water in an average adult, indicating uniform distribution throughout aqueous body compartments without significant accumulation in lipid-rich tissues or extensive plasma protein binding that would restrict distribution. This pharmacokinetic profile is directly responsible for its excellent CSF penetration: because it is small, hydrophilic, and minimally protein-bound, flucytosine distributes freely across the blood-brain barrier and equilibrates into CSF, achieving concentrations that are 70 to 85% of concurrent plasma concentrations. This contrasts sharply with amphotericin B, which is highly lipophilic with a very large volume of distribution (several liters per kilogram) reflecting extensive tissue sequestration, yet paradoxically achieves poor CSF penetration because its large molecular size and lipid associations impair CNS equilibration.
Option B: Option B is incorrect because flucytosine has minimal plasma protein binding (approximately 4%), not 85%; high protein binding would restrict distribution and would explain a small volume of distribution, not a volume equal to total body water, and would impair rather than facilitate CSF penetration.
Option C: Option C is incorrect because a volume of distribution of 0.6 L/kg does not indicate extensive intracellular sequestration; the comparably large tissue-bound volumes of distribution seen with amphotericin B lipid complex are in the range of 100 L/kg, far greater than 0.6 L/kg.
Option D: Option D is incorrect because flucytosine does not selectively concentrate in adipose tissue; it is hydrophilic and poorly lipid-soluble, meaning adipose sequestration does not occur, and its distribution reflects aqueous compartment equilibration rather than lipid depot accumulation.
Option E: Option E is incorrect because flucytosine is not significantly eliminated by biliary excretion or subject to enterohepatic recycling; it is excreted predominantly as unchanged drug in urine, and its volume of distribution reflects tissue distribution, not recirculation kinetics.
8. A nephrologist consults on the appropriate terbinafine dose for a patient with CrCl (creatinine clearance) of 35 mL/min who has confirmed dermatophyte onychomycosis. The consulting pharmacist states that a dose adjustment is warranted. Which statement correctly explains why renal function affects terbinafine dosing despite the drug undergoing primarily hepatic metabolism?
A) Terbinafine is a substrate of renal organic anion transporters (OAT1/OAT3); reduced renal tubular secretion in chronic kidney disease decreases terbinafine clearance and elevates plasma parent drug concentrations independent of hepatic metabolism
B) Terbinafine competes with creatinine for glomerular filtration; as creatinine rises in chronic kidney disease it occupies filtration capacity, reducing terbinafine filtration and prolonging its half-life
C) Terbinafine undergoes significant renal glucuronidation; when glomerular filtration rate falls below 50 mL/min, this renal metabolic pathway is lost and hepatic metabolism becomes saturated, causing parent drug accumulation
D) Although terbinafine undergoes extensive hepatic metabolism, its metabolites are eliminated by renal excretion; in renal impairment, accumulation of these metabolites increases systemic exposure and the risk of adverse effects including hepatotoxicity, requiring an approximately 50% dose reduction when CrCl falls below 50 mL/min
E) Terbinafine dose adjustment in renal impairment is required only because the drug is nephrotoxic at standard doses; the dose reduction is preventive rather than pharmacokinetically driven and does not reflect any change in drug or metabolite clearance
ANSWER: D
Rationale:
Terbinafine is extensively metabolized by the liver through multiple CYP isoforms including CYP2C9, CYP1A2, CYP3A4, and CYP2C8 to multiple inactive metabolites. These metabolites are subsequently eliminated by renal excretion. In patients with renal impairment, reduced glomerular filtration rate decreases the clearance of terbinafine metabolites, leading to their accumulation in plasma. The increased systemic burden of drug and metabolites elevates overall drug exposure and increases the risk of concentration-related adverse effects, including hepatotoxicity. Current prescribing guidance therefore recommends reducing the standard 250 mg once-daily dose by approximately 50% (to 125 mg once daily) when CrCl falls below 50 mL/min, and avoiding the drug entirely in severe renal impairment. This pharmacokinetic rationale — metabolite accumulation from impaired renal elimination — is the basis for the dose adjustment, even though terbinafine itself is not directly renally cleared.
Option A: Option A is incorrect because terbinafine is not a clinically significant substrate of OAT1/OAT3 renal transporters; its metabolism and elimination pathway runs primarily through hepatic CYP metabolism followed by renal excretion of metabolites, not through active renal tubular secretion of the parent drug.
Option B: Option B is incorrect because terbinafine does not compete with creatinine for glomerular filtration slots; glomerular filtration of macromolecules and small organic acids involves different pathways, and this is not an established mechanism for terbinafine-creatinine interaction.
Option C: Option C is incorrect because terbinafine does not undergo significant renal glucuronidation; glucuronidation is a hepatic Phase II reaction, and the drug is not metabolized to a meaningful degree within the kidney.
Option E: Option E is incorrect because the terbinafine dose reduction in renal impairment is pharmacokinetically driven by metabolite accumulation rather than being a prophylactic measure unrelated to drug clearance; the reduced CrCl directly impairs elimination of renally excreted terbinafine metabolites.
9. An infectious disease attending explains to residents why combination therapy with amphotericin B (AmB) and flucytosine reduces the emergence of secondary flucytosine resistance during cryptococcal meningitis treatment compared to flucytosine monotherapy. Which mechanism best accounts for the reduced resistance emergence in the combination regimen?
A) Amphotericin B directly inhibits the mutational machinery of Cryptococcus neoformans by intercalating into fungal DNA, reducing the frequency of spontaneous resistance mutations at cytosine permease and cytosine deaminase loci
B) Amphotericin B rapidly reduces the total viable fungal burden in the cerebrospinal fluid through its fungicidal membrane-disrupting activity; a smaller fungal population contains fewer pre-existing resistant mutants, reducing the probability that flucytosine-resistant subclones will be selected during therapy
C) Amphotericin B competitively inhibits the cytosine permease transporter when used in combination, preventing flucytosine uptake into susceptible fungal cells and thereby masking these cells from flucytosine selection pressure that would otherwise drive resistance
D) Amphotericin B chelates intracellular ergosterol in Cryptococcus neoformans, which paradoxically upregulates cytosine permease expression, increasing flucytosine influx into all cells in the population and eliminating resistant subclones through forced drug accumulation
E) Amphotericin B inhibits the DNA repair machinery in Cryptococcus neoformans by depleting intracellular magnesium, preventing repair of 5-FU-induced DNA strand breaks and thereby eliminating even those cells that have acquired partial resistance mutations
ANSWER: B
Rationale:
Secondary resistance to flucytosine emerges when pre-existing resistant mutants within the fungal population are selectively amplified under drug pressure during monotherapy. In any large fungal population, a small fraction of cells already carry loss-of-function mutations in the flucytosine activation pathway (cytosine permease, cytosine deaminase, or URA enzymes); flucytosine monotherapy kills susceptible cells while leaving these pre-existing resistant mutants to proliferate. The combination with amphotericin B reduces secondary resistance emergence by achieving more rapid fungicidal reduction of the total viable fungal burden. Amphotericin B binds ergosterol in the fungal cell membrane, forming ion-permeable channels that kill cells through membrane disruption. This rapid reduction in total cell numbers — including both susceptible and resistant subclones — limits the absolute number of resistant cells available to be selected and expanded. A smaller population of surviving resistant mutants is less likely to achieve clinical dominance during the treatment course. This probabilistic mechanism is why combination therapy consistently demonstrates superior early fungicidal activity compared to monotherapy in cryptococcal meningitis trials.
Option A: Option A is incorrect because amphotericin B does not intercalate into fungal DNA or directly inhibit fungal mutation machinery; its mechanism is membrane disruption through ergosterol binding, not nucleic acid targeting.
Option C: Option C is incorrect because amphotericin B does not competitively inhibit cytosine permease; if anything, membrane disruption by amphotericin B increases rather than decreases flucytosine uptake — which is the basis for pharmacodynamic synergy, not reduced uptake.
Option D: Option D is incorrect because intracellular ergosterol chelation by amphotericin B is not its mechanism of action; amphotericin B binds ergosterol in the cell membrane to form pores, and this does not paradoxically upregulate cytosine permease.
Option E: Option E is incorrect because amphotericin B does not deplete intracellular magnesium or inhibit DNA repair machinery; this mechanism is not established for amphotericin B, and magnesium depletion-based inhibition of fungal DNA repair is not a recognized pharmacodynamic property.
10. A pharmacology resident asks for a precise description of how griseofulvin disrupts fungal cell division at the molecular level. Which statement most accurately describes griseofulvin's molecular mechanism?
A) Griseofulvin binds to the colchicine site on assembled microtubule polymers and causes their depolymerization by destabilizing lateral protofilament contacts, producing rapid collapse of the mitotic spindle
B) Griseofulvin binds to the plus ends of mitotic spindle microtubules and caps them, preventing both polymerization and depolymerization; static microtubules cannot undergo the dynamic instability required for chromosome segregation
C) Griseofulvin intercalates between tubulin dimers within the microtubule lattice and introduces conformational strain that bends the protofilament, causing progressive microtubule buckling and mitotic arrest
D) Griseofulvin binds to fungal gamma-tubulin at microtubule organizing centers, preventing nucleation of new microtubule polymerization without affecting pre-existing assembled spindle fibers
E) Griseofulvin binds to tubulin monomers and inhibits their polymerization into microtubules, producing abnormal mitotic spindle assembly that results in multinucleated cells unable to complete nuclear division
ANSWER: E
Rationale:
Griseofulvin binds to tubulin monomers — the individual tubulin heterodimer units — and inhibits their self-assembly into microtubule polymers. By preventing polymerization at the monomer level, griseofulvin disrupts the formation of functional mitotic spindle microtubules required for chromosome segregation during fungal cell division. The result is abnormal mitosis producing multinucleated, morphologically aberrant cells that cannot complete cell division. This mechanism is distinct from agents such as the vinca alkaloids (vinblastine, vincristine), which also bind tubulin monomers and inhibit polymerization, or taxanes (paclitaxel), which bind assembled microtubules and stabilize them against depolymerization. Griseofulvin's selectivity for fungal cells over mammalian cells is not based on target specificity (tubulin is present in both) but on selective intracellular concentration: the drug accumulates preferentially in keratinized tissues and in fungal cells.
Option A: Option A is incorrect because griseofulvin does not bind to pre-assembled microtubule polymers to cause depolymerization; it acts at the monomer stage before polymerization occurs. Microtubule depolymerization by binding to assembled polymers describes the mechanism of colchicine and the vinca alkaloids acting on assembled structures.
Option B: Option B is incorrect because griseofulvin does not function as a microtubule plus-end capping agent; it prevents monomer assembly upstream of the polymerization process, rather than capping completed microtubules to suppress dynamic instability.
Option C: Option C is incorrect because griseofulvin does not intercalate between tubulin dimers within the microtubule lattice to cause protofilament buckling; intercalation within assembled lattice structures describes a mechanism not established for griseofulvin.
Option D: Option D is incorrect because griseofulvin does not selectively target gamma-tubulin at microtubule organizing centers; its established binding target is tubulin monomers (alpha-beta tubulin heterodimers), and interference with gamma-tubulin nucleation sites is not the documented mechanism.
11. A patient taking terbinafine for onychomycosis is prescribed codeine for mild post-procedural pain. Two days later she reports that the codeine is providing no pain relief at all. Which pharmacokinetic interaction best explains this patient's inadequate analgesia?
A) Terbinafine induces CYP3A4, accelerating codeine metabolism to norcodeine, which has no analgesic activity, thereby reducing the fraction of codeine available for conversion to morphine
B) Terbinafine inhibits P-glycoprotein in the blood-brain barrier, preventing central nervous system penetration of both codeine and its active metabolite morphine, eliminating the analgesic effect at the mu-opioid receptor
C) Terbinafine inhibits CYP2D6, the enzyme responsible for converting codeine to morphine, reducing morphine production; since codeine itself has minimal intrinsic analgesic activity and requires CYP2D6-mediated O-demethylation to morphine for efficacy, CYP2D6 inhibition produces functional non-response equivalent to the poor metabolizer phenotype
D) Terbinafine competitively displaces codeine from plasma protein binding sites, increasing codeine's renal excretion and reducing its plasma half-life before meaningful morphine conversion can occur
E) Terbinafine inhibits CYP2C9, which metabolizes morphine once it is formed from codeine; by reducing morphine clearance, terbinafine paradoxically increases morphine exposure but the resulting receptor desensitization from excessive morphine signaling reduces perceived analgesia
ANSWER: C
Rationale:
Codeine is a prodrug with minimal intrinsic analgesic activity. Its analgesic effect depends almost entirely on O-demethylation to morphine by CYP2D6 (cytochrome P450 2D6) in the liver. Terbinafine is a potent mechanism-based inhibitor of CYP2D6, irreversibly inactivating the enzyme. When CYP2D6 activity is substantially reduced or eliminated by terbinafine, codeine O-demethylation to morphine is impaired, resulting in very low morphine production. This functionally converts the patient to a poor CYP2D6 metabolizer phenotype — a state in which codeine fails to provide analgesia because the prodrug cannot be activated. This is a clinically important interaction because codeine is commonly used for mild-to-moderate pain, and prescribers may not anticipate analgesic failure in a patient concurrently taking terbinafine. For patients requiring analgesia during terbinafine therapy, drugs that do not depend on CYP2D6 activation (such as non-opioid analgesics or opioids that are not CYP2D6-dependent prodrugs) should be considered.
Option A: Option A is incorrect because terbinafine does not induce CYP3A4; it inhibits CYP2D6. CYP3A4 induction by other drugs (such as rifampin) can accelerate norcodeine formation, but this is not the mechanism for terbinafine, which acts specifically on CYP2D6 to impair morphine production.
Option B: Option B is incorrect because terbinafine does not inhibit P-glycoprotein at the blood-brain barrier in a clinically meaningful way, and inadequate CNS penetration of morphine is not the basis for codeine failure in the setting of terbinafine co-administration; the mechanism is impaired prodrug activation.
Option D: Option D is incorrect because terbinafine does not displace codeine from plasma protein binding to a clinically significant degree, and this would not explain analgesic failure — protein binding displacement would increase free drug levels, not reduce them.
Option E: Option E is incorrect because morphine is primarily glucuronidated by UGT2B7, not metabolized by CYP2C9; terbinafine does not meaningfully inhibit CYP2C9, and reduced morphine clearance leading to receptor desensitization is not the pharmacological explanation for this patient's analgesic failure.
12. A clinical microbiology report returns a blood culture positive for Candida krusei (recently reclassified as Pichia kudriavzevii) in an immunocompromised patient. A resident asks whether flucytosine can be included in the antifungal regimen. Which statement correctly characterizes flucytosine's activity against this organism?
A) C. krusei (P. kudriavzevii) is susceptible to flucytosine at standard doses; susceptibility testing is unnecessary because all Candida species within the krusei clade are reliably flucytosine-sensitive
B) C. krusei (P. kudriavzevii) has intermediate susceptibility to flucytosine; dose escalation to 37.5 mg/kg every 6 hours achieves therapeutic levels above the elevated MIC (minimum inhibitory concentration) and is therefore appropriate
C) C. krusei (P. kudriavzevii) susceptibility to flucytosine is variable and unpredictable; susceptibility testing must be performed before each treatment course because resistance rates differ substantially between geographic regions
D) C. krusei (P. kudriavzevii) is intrinsically resistant to flucytosine; this constitutive resistance is a defining characteristic of the species, making flucytosine inappropriate regardless of in vitro testing results, and alternative antifungals must be selected
E) C. krusei (P. kudriavzevii) is resistant to flucytosine only when grown as a biofilm; planktonic isolates from bloodstream infections remain susceptible and can be treated with standard flucytosine doses targeting a peak concentration of 25 to 50 mg/L
ANSWER: D
Rationale:
Candida krusei (recently reclassified taxonomically as Pichia kudriavzevii) is intrinsically resistant to flucytosine. This intrinsic resistance is a constitutive, species-level characteristic — it is not acquired through selective pressure during treatment and does not require susceptibility testing to detect. The resistance reflects constitutive dysfunction or absence of the flucytosine activation pathway components (cytosine permease and/or cytosine deaminase) in this species, preventing intracellular conversion to the active toxic metabolites. Because the resistance is intrinsic rather than acquired, no dose escalation can overcome it, and flucytosine should not be used against C. krusei regardless of clinical context or testing results. Additionally, C. krusei is also intrinsically resistant to fluconazole, making echinocandins or amphotericin B the preferred agents for systemic C. krusei infections.
Option A: Option A is incorrect because C. krusei is intrinsically resistant to flucytosine; it is not susceptible at any standard dose, and the statement that all Candida species within the krusei clade are reliably sensitive is incorrect.
Option B: Option B is incorrect because intrinsic resistance cannot be overcome by dose escalation; the resistance mechanism reflects absence of functional drug activation enzymes, not a pharmacokinetic issue of achieving sufficient drug concentrations above an MIC.
Option C: Option C is incorrect because C. krusei resistance to flucytosine is intrinsic and species-defining, not geographically variable; it does not require institution- or region-specific susceptibility testing because it is uniformly present across isolates.
Option E: Option E is incorrect because C. krusei resistance to flucytosine is not limited to biofilm growth conditions; it is present in all growth forms including planktonic isolates in bloodstream infections.
13. An infectious disease fellow asks a pharmacist to confirm the correct flucytosine dosing regimen for induction therapy of cryptococcal meningitis when combined with amphotericin B in a patient with normal renal function. Which of the following correctly describes the standard induction dosing?
A) Flucytosine 25 mg/kg orally or intravenously every 6 hours (100 mg/kg/day in four divided doses) for 1 to 2 weeks, with TDM (therapeutic drug monitoring) guiding dose adjustment based on 2-hour post-dose peak concentrations targeting 25 to 50 mg/L
B) Flucytosine 50 mg/kg orally once daily for 4 weeks during induction, with TDM performed only if nephrotoxicity from concurrent amphotericin B causes a greater than 50% rise in serum creatinine
C) Flucytosine 10 mg/kg intravenously every 12 hours for 2 weeks, using the intravenous route exclusively because oral bioavailability is insufficient to achieve therapeutic cerebrospinal fluid (CSF) concentrations during active central nervous system infection
D) Flucytosine 25 mg/kg orally twice daily for 6 weeks through the entire induction and consolidation phases, with a single TDM measurement at week 2 to confirm adequate levels before continuing
E) Flucytosine 100 mg/kg as a single daily oral dose for 2 weeks, exploiting concentration-dependent antifungal pharmacodynamics to maximize the peak-to-MIC ratio in cerebrospinal fluid and limit exposure duration
ANSWER: A
Rationale:
The standard flucytosine induction dose for cryptococcal meningitis in patients with normal renal function is 25 mg/kg orally or intravenously four times daily (every 6 hours), providing 100 mg/kg/day, for 1 to 2 weeks combined with amphotericin B. This regimen is derived from pharmacokinetic-pharmacodynamic modeling and supported by clinical trial evidence including the ACTA (Advancing Cryptococcal Meningitis Treatment for Africa) trial and studies informing the WHO 2022 cryptococcal disease guidelines. TDM is mandatory throughout induction, targeting a 2-hour post-dose peak concentration of 25 to 50 mg/L (some protocols targeting 40 to 60 mg/L for CNS infections) while keeping trough concentrations below 100 mg/L to avoid concentration-dependent myelosuppression. The four-times-daily dosing interval reflects flucytosine's plasma half-life of approximately 3 to 6 hours in patients with normal renal function and its time-dependent pharmacodynamics.
Option B: Option B is incorrect because once-daily dosing at 50 mg/kg is not the established regimen; the pharmacokinetic basis for flucytosine dosing uses divided doses throughout the day to maintain steady-state concentrations within the therapeutic window, and a four-week induction duration substantially exceeds the standard 1 to 2 weeks.
Option C: Option C is incorrect because flucytosine oral bioavailability exceeds 90%, making it pharmacokinetically interchangeable with the intravenous route; there is no pharmacokinetic rationale for mandating intravenous administration for CNS infections, and the 10 mg/kg q12h dose provides significantly less drug exposure than the standard 25 mg/kg q6h.
Option D: Option D is incorrect because the standard induction duration is 1 to 2 weeks, not 6 weeks through both induction and consolidation phases; after induction, the regimen transitions to consolidation with fluconazole (the amphotericin B and flucytosine combination is not maintained for 6 weeks).
Option E: Option E is incorrect because flucytosine exhibits time-dependent rather than concentration-dependent pharmacodynamics; its efficacy correlates with duration above the MIC, not with peak concentration ratios, making once-daily high-dose administration pharmacodynamically inappropriate.
14. A dermatologist evaluating two children with tinea capitis receives culture results: one child has Trichophyton tonsurans and the other has Microsporum canis. She asks a clinical pharmacologist whether the same systemic antifungal should be used for both. Which statement correctly describes the evidence-based species-specific drug selection for these two organisms?
A) Terbinafine is preferred for both T. tonsurans and M. canis because its mechanism of squalene epoxidase inhibition provides equivalent in vitro MICs against all dermatophyte species, making species identification irrelevant to drug selection
B) Terbinafine is preferred for T. tonsurans tinea capitis based on superior mycological cure rates demonstrated in comparative trials; griseofulvin may be preferred for M. canis tinea capitis because terbinafine achieves lower mycological cure rates against Microsporum species compared to Trichophyton species
C) Griseofulvin is preferred for both T. tonsurans and M. canis because it has the longest regulatory approval record for tinea capitis and terbinafine lacks sufficient pediatric safety data for use in children under 12 years of age
D) Fluconazole is the preferred agent for both species because it achieves superior keratin penetration compared to either terbinafine or griseofulvin and has the most favorable side effect profile for pediatric patients
E) Drug selection between terbinafine and griseofulvin for tinea capitis should be made exclusively on the basis of the child's weight and the availability of appropriate pediatric formulations, as clinical efficacy is equivalent for both organisms with either drug
ANSWER: B
Rationale:
Species identification is clinically relevant in tinea capitis because comparative trials have demonstrated differential efficacy for terbinafine across dermatophyte species. For Trichophyton tonsurans, which is the predominant cause of tinea capitis in North America and many parts of the world, terbinafine has demonstrated superior mycological cure rates compared to griseofulvin in randomized controlled trials and is now preferred in most guidelines for T. tonsurans disease. For Microsporum canis, however, multiple comparative studies have shown that terbinafine achieves lower mycological cure rates than it does against Trichophyton species, while griseofulvin maintains reliable efficacy. Griseofulvin is therefore preferred or considered equally acceptable as a first-line option for M. canis tinea capitis in many guidelines. This distinction requires fungal culture identification before initiating therapy wherever feasible.
Option A: Option A is incorrect because equivalent in vitro MICs do not reliably predict equivalent clinical outcomes; clinical trial data for tinea capitis demonstrate species-specific differences in mycological cure rates that are not explained by MIC values alone, and the statement that species identification is irrelevant is contradicted by published comparative trial results.
Option C: Option C is incorrect because terbinafine does have established pediatric safety data and dosing recommendations for children (weight-based dosing), and is approved for pediatric use in tinea capitis in many jurisdictions; the premise that it lacks pediatric safety data under age 12 is inaccurate.
Option D: Option D is incorrect because fluconazole is not the preferred first-line agent for tinea capitis caused by either T. tonsurans or M. canis; it is used off-label in some centers but is not established as superior to terbinafine or griseofulvin in comparative trials.
Option E: Option E is incorrect because clinical efficacy is not equivalent for both organisms with either drug — the species-specific efficacy difference for terbinafine between Trichophyton and Microsporum species is the central clinical distinction that necessitates culture identification.
15. A physician is counseling a patient before starting a 12-week course of terbinafine for onychomycosis. The patient asks about the risk of liver damage she has read about online. Which statement most accurately characterizes terbinafine hepatotoxicity?
A) Terbinafine hepatotoxicity is dose-dependent and predictable; it occurs in approximately 5 to 10% of patients at the standard 250 mg daily dose and can be reliably prevented by reducing the dose to 125 mg daily in all patients regardless of renal function
B) Terbinafine hepatotoxicity is a class effect shared equally by all antifungal agents including azoles and echinocandins, and the risk with terbinafine is not meaningfully different from that of fluconazole at equivalent treatment durations
C) Terbinafine hepatotoxicity manifests exclusively as a cholestatic pattern with elevated bilirubin and alkaline phosphatase; hepatocellular injury with elevated ALT (alanine aminotransferase) does not occur with this drug
D) Terbinafine-induced liver injury is confined to patients with pre-existing liver disease or alcohol use disorder; patients without these risk factors face no clinically meaningful hepatotoxicity risk and require no liver function monitoring
E) Terbinafine hepatotoxicity is rare (estimated incidence approximately 1 in 50,000 to 1 in 120,000 treated patients) but can be serious; the mechanism is idiosyncratic and immune-mediated rather than dose-dependent, making it unpredictable, and baseline LFTs (liver function tests) are recommended in high-risk patients before starting treatment
ANSWER: E
Rationale:
Terbinafine carries a rare but clinically significant risk of serious hepatotoxicity, including symptomatic hepatitis, cholestatic jaundice, hepatic failure, and death. The estimated incidence of serious liver injury is approximately 1 in 50,000 to 1 in 120,000 treated patients — uncommon but meaningful given the large population prescribed terbinafine for onychomycosis. The mechanism appears to be idiosyncratic and immune-mediated rather than dose-dependent, which has two important clinical implications: first, it cannot be reliably predicted or prevented by reducing the dose; second, monitoring alone cannot guarantee safety because the reaction may develop without warning. Asymptomatic LFT elevations are more common and generally transient. Current guidance recommends obtaining baseline LFTs before starting terbinafine in patients with pre-existing liver disease or significant alcohol use, and discontinuing the drug if ALT or AST rises above 3 times ULN with symptoms or above 5 times ULN without symptoms. Patients should be counseled to report jaundice, dark urine, or right upper quadrant pain.
Option A: Option A is incorrect because terbinafine hepatotoxicity is idiosyncratic rather than dose-dependent; it is not a predictable complication occurring in 5 to 10% of patients at standard doses, and dose reduction to 125 mg does not reliably prevent it in all patients.
Option B: Option B is incorrect because terbinafine hepatotoxicity is not a uniform class effect equivalent to that of all other antifungal agents; the risk profile, mechanism, and clinical presentation differ between antifungal classes, and fluconazole-associated hepatotoxicity has its own distinct characteristics.
Option C: Option C is incorrect because terbinafine-induced liver injury can manifest as hepatocellular injury with elevated ALT as well as cholestatic patterns; cases of both hepatocellular and mixed hepatocellular-cholestatic injury have been reported.
Option D: Option D is incorrect because while pre-existing liver disease and alcohol use are risk factors that warrant baseline monitoring, idiosyncratic reactions by definition can occur in patients without identifiable predisposing risk factors; the drug is not free of hepatotoxicity risk in otherwise healthy patients.
16. A clinical pharmacologist is asked to explain why flucytosine's antifungal activity is described as disrupting both DNA synthesis and RNA function, rather than targeting only one nucleic acid pathway. Which statement accurately describes flucytosine's dual mechanism at the molecular level?
A) Flucytosine is converted intracellularly to two active metabolites: 5-fluorouracil (5-FU), which intercalates directly into fungal chromosomal DNA and causes strand breaks, and fluorocytidine triphosphate, which blocks RNA polymerase by competing with cytidine triphosphate for the enzyme active site
B) Flucytosine is phosphorylated directly to a single bifunctional nucleotide that simultaneously occupies both the thymidylate synthase active site and the RNA polymerase catalytic center, inhibiting both enzymes through a single molecular interaction
C) Flucytosine is converted to 5-fluorouracil, which is then degraded by dihydropyrimidine dehydrogenase to fluoroalanine; fluoroalanine inhibits alanine racemase in fungal cell wall synthesis and, separately, is incorporated into ribosomal RNA as a false amino acid
D) After intracellular conversion to 5-fluorouracil (5-FU), flucytosine's activity proceeds through two parallel pathways: 5-FU is converted to FdUMP (fluorodeoxyuridine monophosphate), which inhibits thymidylate synthase and thereby blocks DNA synthesis; and 5-FU is incorporated as FUTP (fluorouridine triphosphate) into RNA, disrupting RNA function and impairing protein synthesis
E) Flucytosine inhibits DNA synthesis by blocking the fungal ribonucleotide reductase enzyme that converts ribonucleoside diphosphates to deoxyribonucleoside diphosphates; RNA disruption is an indirect consequence of the resulting imbalance in nucleotide pool ratios rather than a direct effect of any flucytosine metabolite
ANSWER: D
Rationale:
After entering the fungal cell via cytosine permease and conversion to 5-fluorouracil (5-FU) by cytosine deaminase, flucytosine's active metabolite 5-FU is further processed through two distinct and parallel intracellular pathways. In the first pathway, 5-FU is converted to FdUMP (fluorodeoxyuridine monophosphate), which forms a stable ternary complex with thymidylate synthase and the cofactor 5,10-methylenetetrahydrofolate, irreversibly inhibiting the enzyme. Because thymidylate synthase catalyzes the synthesis of thymidine monophosphate (TMP) — the only de novo source of thymidine for DNA synthesis — its inhibition depletes the thymidine pool and blocks DNA replication. In the second pathway, 5-FU is converted to FUTP (fluorouridine triphosphate), which is directly incorporated into nascent RNA in place of uridine triphosphate (UTP). FUTP incorporation into RNA disrupts RNA structure and function, impairing ribosomal RNA processing and messenger RNA translation, which impairs protein synthesis. The simultaneous disruption of DNA synthesis (via FdUMP/thymidylate synthase) and RNA function (via FUTP incorporation) constitutes the dual mechanism responsible for flucytosine's antifungal activity.
Option A: Option A is incorrect because 5-FU does not cause DNA strand breaks through intercalation; it inhibits thymidylate synthase via FdUMP (a covalent enzyme inhibition mechanism) rather than intercalating into DNA, and the second pathway involves FUTP incorporation into RNA, not fluorocytidine triphosphate blocking RNA polymerase.
Option B: Option B is incorrect because flucytosine does not act through a single bifunctional nucleotide simultaneously occupying two enzyme active sites; the dual mechanism involves two structurally distinct metabolites (FdUMP and FUTP) acting at two separate enzymatic and structural targets.
Option C: Option C is incorrect because fluoroalanine is not a known metabolite of 5-FU in antifungal activity, and flucytosine's mechanism does not involve alanine racemase inhibition or incorporation as a false amino acid into ribosomal RNA.
Option E: Option E is incorrect because flucytosine does not inhibit ribonucleotide reductase; this enzyme is the target of hydroxyurea, not of flucytosine, and flucytosine's RNA disruption is a direct effect of FUTP incorporation rather than an indirect consequence of altered nucleotide pool ratios.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.